ArticleJournal of medical physics
Dosimetric Evaluation of Three-dimensional Conformal Radiotherapy, RapidArc, and Hybrid RapidArc Radiotherapy Techniques for Left-sided Breast Cancer.
Article in Journal of medical physics. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to assess the irradiation techniques-three-dimensional conformal radiotherapy (3DCRT), RapidArc (RArc), and hybrid RapidArc (h-RArc)-for left-sided breast cancer patients, focusing on dose distribution in the planning target volume (PTV) and organs at risks (OARs). Materials and Methods: This study enrolled 20 patients diagnosed with early-stage left-sided breast cancer. All patients received a prescribed dose of 40.05 Gy in 15 fractions (2.67 Gy per fraction), optimized to achieve 95% dose coverage to 95% of the PTV. The dosimetric variations across the three treatment plans for the 20 patients were examined using a one-way ANOVA test. Results: In the 3DRCT plan, D95% of the PTV was 37.21 ± 0.51 Gy. This value was significantly increased to 39.43 ± 0.27 Gy in the RArc plan ( Conclusions: h-RArc treatment plans for breast cancer may be recommended due to their superior and consistent PTV dose coverage and sparing of OARs, in comparison to both 3DRCT and RArc plans. These h-RArc plans are characterized by reduced MU and beam on time, as well as a less low volume dose when compared to RArc plans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.